Lynch & Associates IN Sells 3,809 Shares of Pfizer Inc. (NYSE:PFE)

Lynch & Associates IN cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 89,748 shares of the biopharmaceutical company’s stock after selling 3,809 shares during the period. Lynch & Associates IN’s holdings in Pfizer were worth $2,381,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in PFE. Strategic Financial Concepts LLC acquired a new stake in Pfizer in the 2nd quarter worth about $38,000. Quest Partners LLC bought a new position in Pfizer in the second quarter valued at about $570,000. Angeles Wealth Management LLC lifted its holdings in Pfizer by 24.0% during the 2nd quarter. Angeles Wealth Management LLC now owns 11,580 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 2,239 shares during the period. AGF Management Ltd. increased its position in shares of Pfizer by 6.7% during the second quarter. AGF Management Ltd. now owns 1,223,841 shares of the biopharmaceutical company’s stock worth $34,243,000 after buying an additional 76,464 shares during the period. Finally, HHM Wealth Advisors LLC lifted its holdings in Pfizer by 9.3% in the second quarter. HHM Wealth Advisors LLC now owns 6,311 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 538 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on PFE. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Down 0.5 %

Shares of PFE traded down $0.13 during mid-day trading on Friday, reaching $26.73. The company had a trading volume of 32,549,836 shares, compared to its average volume of 35,293,961. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $151.48 billion, a price-to-earnings ratio of 36.12, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The firm has a 50-day moving average price of $26.21 and a 200 day moving average price of $28.05.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.43%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.43%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.